Teropavimab

Phase II trial results demonstrate that lenacapavir combined with two broadly neutralizing antibodies (teropavimab and zinlirvimab) maintained viral suppression in 96% of participants over 26 weeks, comparable to daily oral regimens.

Real-world data presented at CROI 2025 demonstrates zero HIV acquisitions and high persistence with Apretude (cabotegravir LA) for PrEP across diverse populations, reinforcing its effectiveness in HIV prevention.

St. Jude Children's Research Hospital's HIV clinical research program explores innovative long-acting treatments, including a groundbreaking six-month regimen combining antibodies and capsid inhibitors.

The ACTG has initiated the ACACIA (A5417) study, a Phase 2 trial, to assess the safety and efficacy of broadly neutralizing antibodies (bNAbs) in HIV treatment.

Gilead's PURPOSE 2 trial results show lenacapavir's potential as a twice-yearly HIV prevention option for cisgender men and gender-diverse individuals.